Aktuellt
SENASTE
Fluicell AB (publ) (”Fluicell” or “the Company”) offers innovative R&D instruments for both single-cell analysis and 3D bioprinting business segments in which we forecast will enter a fast-growing pace, where a revenue of SEK 68.6m is estimated for the year 2026 for the Company. Furthermore, Fluicell is developing tissue engineered products, targeting areas such as cardiac repair, diabetes, and eye disorders, where successful progress in related projects constitute as strong value drivers ahead. Based on an applied P/S-multiple of 5.5x on estimated revenues and a discount rate of 12%, this yields an implied value per share of SEK 9.8 in a Base scenario, where steps in the right direction are expected to reduce the current valuation discount.
LÄS MER
